Ligand Pharmaceuticals (LGND) Income from Non-Controlling Interests (2014 - 2015)
Ligand Pharmaceuticals (LGND) posted Income from Non-Controlling Interests of $49000.0 for Q1 2023, up 240.0% sequentially from -$35000.0 in Q2 2022, and up 142.98% YoY from $20166.1 in Q1 2022.
Powered by 
Analysis
Ligand Pharmaceuticals (LGND) Income from Non-Controlling Interests (2014 - 2015) Analysis & Trends
Ligand Pharmaceuticals has reported Income from Non-Controlling Interests for 6 years, with the latest figure at $49000.0 in Q1 2023.
- Quarterly Income from Non-Controlling Interests rose 142.98% year-over-year to $49000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was -$105000.0 (up 39.66% YoY) and the FY2015 annual result came in at $2.4 million, up 310.25% from the prior year.
- Income from Non-Controlling Interests advanced to $49000.0 in Q1 2023 per LGND's latest filing, from -$35000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $49000.0 in Q1 2023 and troughed at -$114000.0 in Q1 2022.
- A 3-year average of -$32000.0 and a median of -$35000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests slumped 600.0% in 2022, then jumped 142.98% in 2023.
- Over 3 years, Income from Non-Controlling Interests stood at -$5000.0 in 2021, then plunged by 600.0% to -$35000.0 in 2022, then jumped by 240.0% to $49000.0 in 2023.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $49000.0, -$35000.0, and -$114000.0 for Q1 2023, Q2 2022, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Ligand Pharmaceuticals | 5.77 Bn | 4.41 Bn | 60.48 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2015 | -1.54 Mn |
| Mar 31, 2015 | -843,000.00 |
| Dec 31, 2014 | -325,000.00 |
| Sep 30, 2014 | -503,000.00 |
| Jun 30, 2014 | -304,000.00 |